Pacific Biosciences of California Inc. stocks have been trading up by 7.91 percent after favorable sequencing technology adoption news.
Click Here for a Millionaire's POV on Trading PACB
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- PacBio announced a multi-year strategic collaboration with Verily Health to integrate PacBio HiFi long-read sequencing into Verily’s governed data and AI platform, creating AI-ready clinico-genomic datasets for biomedical discovery and model development.
- The Verily collaboration aims to extend into complex long-read programs for research, biopharma, and population genomics, leveraging Verily’s cloud, multimodal health data, and AI capabilities at population scale.
- PacBio announced a collaboration with AI drug discovery firm TychoBio, which will use PacBio’s HiFi and Kinnex long-read RNA sequencing technologies on more than 10,000 samples to generate full-length RNA datasets for training AI models that design and evaluate RNA therapies.
- The TychoBio deal embeds PacBio’s technology directly into TychoBio’s RNA therapy design workflow, targeting RNA therapeutics for rare diseases and positioning PacBio as a key data provider for AI-driven drug discovery and rare disease research.
- PacBio set the date and webcast details for its Q3 2026 earnings conference call, without providing any preliminary financial or operational results.
Live Update At 12:34:29 EDT: On Wednesday, October 21, 2026 Pacific Biosciences of California Inc. stock [NASDAQ: PACB] is trending up by 7.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
PACB is trading like a classic high-volatility growth story. Over the last few weeks, Pacific Biosciences of California Inc. has swung from a close near $2.72 on 2026/10/07 down to $1.73 on 2026/10/16, before grinding back to about $2.12 on 2026/10/21. That’s a sharp pullback from early-October highs above $3, followed by a steady bounce — prime territory for active trading.
Intraday, PACB’s 5‑minute chart shows a slow, controlled uptrend from a $1.97 open into the low $2.18 range by midday, with tight ranges and higher lows. That kind of stair-step price action tells traders that dip buyers are still in control, even if the big-picture chart is choppy.
More Breaking News
- SSPC Leverage Shares 2X Short SPCX Daily Shows Volatile Turn
- AHT Stock Draws Firepower As Advisor Waives Fees, Pledges Share Buys
- SPCX Stock Rallies As Spectrum Deals And AI Push Draw Traders
- YMAT Stock Explodes As Houston Carbon-Fiber Bet Ignites Trading
Fundamentally, PACB is still a heavy cash-burn name. Quarterly revenue sits around $39.0M, but net loss is roughly $44.7M, leaving profit margins deeply negative and EBITDA in the red. Free cash flow was about -$39.2M last quarter. The balance sheet, however, shows a strong liquidity cushion: a current ratio near 4.9 and cash, equivalents, and short-term investments of roughly $236.9M. For traders, that combination — solid cash runway, high losses, and hot AI/genomics narratives — often fuels sharp momentum swings around news and earnings.
Why Traders Are Watching PACB Right Now
Traders are crowding around PACB because the story just shifted from “cool tech” to “embedded in AI health platforms.” Pacific Biosciences of California Inc. locked in a multi-year strategic collaboration with Verily Health, and that matters. Verily runs a governed, cloud-based health data and AI platform aimed at big population and biopharma programs. Plugging PacBio HiFi long-read sequencing into that stack turns PACB from a pure hardware seller into a core data engine for large-scale clinico-genomic projects.
According to the Verily news, PACB’s workflows will be tightly integrated so Verily can build AI-ready datasets at population scale. That means PACB is positioned upstream of long-term research, biopharma, and population genomics pipelines rather than just one-off instrument orders. Traders watching AI, genomics, and “picks-and-shovels” data plays should see this as validation that PacBio’s long-read tech is becoming infrastructure, not a side tool.
The TychoBio deal pushes the same theme from another angle. PACB’s HiFi and Kinnex long-read RNA sequencing will power more than 10,000 samples to train AI models that design RNA therapies for rare diseases. That’s not a small pilot — that’s workflow-level integration. TychoBio is embedding PacBio directly into its RNA therapy design process, which signals repeat sequencing demand every time TychoBio scales or launches new programs.
Put together, these collaborations frame PACB as a key data provider across two of the hottest trading themes: AI-driven drug discovery and population-scale genomics. No financial terms are disclosed, so traders should not assume instant revenue spikes. But from a narrative standpoint, PACB now sits at the crossroads of sequencing, cloud health data, and AI — a combo that often attracts momentum flows when charts line up with headlines.
Conclusion
For active traders, PACB is now a classic story-plus-chart setup. On the story side, Pacific Biosciences of California Inc. has stacked two meaningful AI collaborations in a short window: Verily on the population-scale, clinico-genomic side and TychoBio in AI-powered RNA drug design for rare diseases. Both embed PacBio technology directly into ongoing workflows, which is exactly what growth-focused traders want to see in a volatile small-cap genomics name.
On the numbers side, PACB remains a high-risk, high-reward profile. Revenue is growing but still overshadowed by large operating losses and negative free cash flow. The strong liquidity position buys time, yet the income statement reminds traders this is far from a steady, cash-generating business. That combination explains the rollercoaster from above $3 down into the $1.70s and back over $2 — this is a battleground ticker. For that reason, risk management has to sit at the center of any PACB trading plan. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” That mindset fits this ticker well, where volatility and sharp reversals can punish undisciplined traders.
Heading into the upcoming Q3 2026 earnings call, traders will be watching to see how much, if at all, these Verily and TychoBio collaborations start to show up in bookings, backlog, or guidance commentary. Until then, PACB remains a news-driven, momentum-friendly stock. In Tim Sykes’ words, “Patterns repeat, but only for traders who are prepared — study the chart, understand the catalyst, and always, always focus on risk first.” This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.